Skip to main content

LAVLI - A New Autoinflammatory DisorderNIH researchers have have described a novel autoinflammatory disorder called "L

Social Author Name
Dr. John Cush
Tweet Content

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/RYmb3QFB1T https://t.co/sn5hwVxwPk

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for th

Social Author Name
Dr. John Cush
Tweet Content
2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/lvPO26S0k6 https://t.co/cQtiEctrTR

30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presenc

Social Author Name
Dr. John Cush
Tweet Content
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj

Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities

Social Author Name
Dr. John Cush
Tweet Content
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among

Social Author Name
Dr. John Cush
Tweet Content
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running an

Social Author Name
Dr. John Cush
Tweet Content
Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow. https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe

Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72)

Social Author Name
Dr. John Cush
Tweet Content
Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72) & low fat (OR 0.84) diet reduce all cause mortality; Med-diet also reduced CV mortality (0.55), stroke (0.65) & non-fatal MI (0.48) https://t.co/ibUknLlwOx https://t.co/zRtvXObvg3

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomi

Social Author Name
Dr. John Cush
Tweet Content
RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u

There are 27 US States where Nurse Practitioners have "Full Practice Authority" - including WA, OR, NV, ID, UT, MT, AZ,

Social Author Name
Dr. John Cush
Tweet Content
There are 27 US States where Nurse Practitioners have "Full Practice Authority" - including WA, OR, NV, ID, UT, MT, AZ, CO, WY, NM, ND, SD, NE, KS, Minn, NY, ME, VT, NH, MA, CT, RI, MD, DE, DC https://t.co/hA9Sd63bDW https://t.co/9MM6CTH4gX
Subscribe to
×